Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trospium chloride inhalation

Next Previous
X
Search
Drug Profile

Trospium chloride inhalation

Alternative Names: ALKS 27; TrIP

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alkermes
  • Developer Alkermes plc
  • Class Antispasmodics; Benzhydryl compounds; Benzilates; Esters; Nortropanes; Small molecules; Spiro compounds; Urologics
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 19 Feb 2009 Phase-II clinical trials in Chronic obstructive pulmonary disease in USA (Inhalation)
  • 01 Oct 2007 Interim results from a phase IIa clinical trial in patients with Chronic obstructive pulmonary disease added to the adverse events and Respiratory Tract Disorders therapeutic trials sections
  • 26 Apr 2007 Phase-I/II clinical trials in Chronic obstructive pulmonary disease in USA (Inhalation)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top